Controlling sialorrhoea: A review of available treatment options

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 9, 2005, Pages 1551-1554

  Potulska, Anna ^a   Friedman, Andrzej ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Drooling; Salivary glands; Sialorrhoea; Treatment

Indexed keywords

AMANTADINE; BENZATROPINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; LEVODOPA; PIRENZEPINE; SCOPOLAMINE; TRIHEXYPHENIDYL;

AMYOTROPHIC LATERAL SCLEROSIS; BEHAVIOR DISORDER; CEREBRAL PALSY; CONFUSION; CONSTIPATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHAGIA; EAR DISEASE; FACE MUSCLE; GASTROINTESTINAL TUMOR; HALLUCINATION; HUMAN; HYPERSALIVATION; IRRITABILITY; LARYNX DISORDER; MEDICAL DECISION MAKING; NEUROLOGIC DISEASE; PARKINSON DISEASE; RESPIRATORY TRACT TUMOR; REVIEW; SIDE EFFECT; SPEECH THERAPY; SURGICAL TECHNIQUE; SWALLOWING; SWEATING; SYMPTOMATOLOGY; TREATMENT PLANNING; UPPER GASTROINTESTINAL TRACT; UPPER RESPIRATORY TRACT; URINE RETENTION; VISUAL IMPAIRMENT; XEROSTOMIA;

BOTULINUM TOXIN TYPE A; CHOLINERGIC ANTAGONISTS; CHRONIC DISEASE; CLINICAL TRIALS; DOPAMINE AGENTS; GLYCOPYRROLATE; HUMANS; LEVODOPA; PRACTICE GUIDELINES; SALIVATION; SIALORRHEA;

EID: 23644448108     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.9.1551     Document Type: Review

References (23)

1. HOCKSTEIN NG, SAMADI DS, GENDRON K, HANDLER SD: Sialorrhea: a management challenge. Am. Fam. Physician (2004) 69(11):2628-2634.
2. BERWECK S, SCHWERIN A, HEINEN F: Management of drooling: 10 years after the Consortium on Drooling 1990. Dev. Med. Child Neurol. (2003) 45(12):845.
3. BREI TJ: Management of drooling. Semin. Pediatr. Neurol. (2003) 10(4):265-270.
4. TAHMASSEBI JF, LUTHER F: Relationship between lip position and drooling in children with cerebral palsy. Eur. J. Paediatr. Dent. (2004) 5(3):151-156.
5. SAVARESE R, DIAMOND M, ELOVIC E, MILLIS SR: Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am. J. Phys. Med. Rehabil. (2004) 83(4):304-311.
6. BUSHARA KO: Sialorrhea in amyotropic lateral sclerosis: a hypothesis of a new treatment-botulinum toxin A injections of the parotid glands. Med. Hypotheses (1997) 48(4):337-339.
7. FORSHEW DA, BROMBERG MB: A survey of clinicians' practice in the symptomatic treatment of ALS. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2003) 4(4):258-263.
8. FRIEDMAN A, POTULSKA A: Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat. Disord. (2001) 7(4):329-332.
9. KAHL KG, HAGENAH J, ZAPF S, TRILLENBERG P, KLEIN C, LENCER R: Botulinum toxin as an effective treatment of clozapine-induced hypersalivation. Psychopharmacology (2004) 173(1-2):229-230.
10. SHARMA A, RAMASWAMY S, DAHL E, DEWAN V: Intraoral application of atropine sulfate ophthalmic solution for clozapine-induced sialorrhea. Ann. Pharmacother. (2004) 38(9):1538.
11. GAFTANYUK O, TRESTMAN RL: Scolpolamine patch for clozapine-induced sialorrhea. Psychiatr. Serv. (2004) 55(3):318.
12. LAPID O, KREIGER Y, SAGI A: Transdermal scopolamine use for postrhytidectomy sialocele. Aesthetic Plast. Surg. (2004) 28(1):24-28.
13. SPINKS AB, WASIAK J, VILLANUEVA EV, BERNATH V: Scopolamine for preventing and treating motion sickness. Cochrane Database Syst. Rev. (2004) 3:CD002851.
14. SCHNEIDER B, WEIGMANN H, HIEMKE C, WEBER B, FRITZE J: Reduction of clozapine-induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry (2004) 37(2):43-54.
15. FREUDENREICH O, BEEBE M, GOFF DC: Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series. J. Clin. Psychopharmacol. (2004) 24(1):98-100.
16. WEBBER MA, SZWAST SJ, STEADMAN TM et al.: Guanfacine treatment ofclozapine-induced sialorrhea. J. Clin. Psychopharmacol. (2004) 24(6):675-676.
17. CORDIVARI C, MISRA VP, CATANIA S, LEES AJ: New therapeutic indications for botulinum toxins. Mov. Disord. (2004) 19 (Suppi.8):S157-S161.
18. DOGU O, APAYDIN D, SEVIM S, TALAS DU, ARAL M: Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin. Neurol. Neurosurg. (2004) 106(2):93-96.
19. ELLIES M, GOTTSTEIN U, ROHRBACH-VOLLAND S, ARGLEBE C, LASKAWI R: Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis. Laryngoscope (2004) 114(10):1856-1860.
20. KAHL KG, TRILLENBERG P, KORDON A, LENCER R, KLEIN C, HAGENAH J: Pharmacological strategies for clozapine-induced hypersalivation: treatment with botulinum toxin B in one patient and review of the literature. Nervenarzt (2005) 76(2):205-208.
21. NAUMANN M, JOST W: Botulinum toxin treatment of secretory disorders. Mov. Disord. (2004) 19 (Suppl. 8):S137-S141.
22. ONDO WG, HUNTER C, MOORE W: A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology (2004) 62(1):37-40.
23. HAN S, ISAACSON G: Recurrent pneumoparotid: cause and treatment. Otolaryngol Head Neck Surg. (2004) 131(5):758-761.